Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Moderator

Hannah Brown, MD

Assistant Professor
Department of Psychiatry
Boston University
Chobanian and Avedisian School of Medicine
Boston, Massachusetts, United States

Disclosures

Hannah Brown, MD, has no relevant financial relationships.

Faculty

Alan Breier, MD

Professor of Psychiatry
Indiana University School of Medicine
Indianapolis, Indiana, United States

Disclosures

Alan Breier, MD, has the following relevant financial relationships:
Consultant or advisor for: Arrivo Bioventures; BioXcel Therapeutics; Karuna Therapeutics; Neumarker Inc.; Perception Neuroscience; Sirtsei Pharmaceuticals, Inc.
Stock options from: Karuna Therapeutics; Perception Neuroscience
Owns stock (publicly traded) in: Karuna Therapeutics

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra
Northwell, New York
Professor of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany

Disclosures

Christoph U. Correll, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Allergan, Inc.; Angelini Pharma; Aristo Pharma (former); Boehringer Ingelheim Pharmaceuticals, Inc.; Cardio Diagnostics; Cerevel Therapeutics; CNX Therapeutics (former); COMPASS Pathways; Darnitsa (former); Gedeon Richter; Hikma Pharmaceuticals (former); Holmusk; Intra-Cellular Therapies, Inc.; Janssen/Johnson and Johnson; Karuna Therapeutics; LB Pharma; Lundbeck, Inc.; MedAvante-ProPhase; MedinCell; Merck; Mindpax; Mitsubishi Tanabe Pharma Corporation (former); Mylan Laboratories Inc.; Neurocrine Biosciences, Inc.; Newron Pharmaceuticals S.p.A. (former); Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Pharmabrain; PPD Biotech; Recordati; Relmada Therapeutics, Inc.; Reviva Pharmaceuticals Inc.; ROVI; Seqirus; SERVIER; SK Life Science; Sunovion Pharmaceuticals Inc.; Sun Pharmaceutical Industries, Ltd. (former); Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company; Teva Pharmaceuticals; Viatris
Speaker or member of speakers bureau for: AbbVie Inc.; Angelini; Aristo Pharma; Darnitsa; Gedeon Richter; Hikma Pharmaceuticals; Intra-Cellular Therapies, Inc.; Janssen/Johnson and Johnson; Lundbeck, Inc.; Mitsubishi Tanabe Pharma Corporation; Mylan Laboratories Inc.; Otsuka Pharmaceutical Co., Ltd.; Recordati; Seqirus; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceutical Company; Viatris
Research funding from: Janssen; Takeda Pharmaceutical Company
Stock options from: Cardio Diagnostics; LB Pharma; Mindpax; Quantic

Editor

Frances McFarland, PhD, MA

Medical Education Director, Medscape, LLC

Disclosures

Frances McFarland, PhD, MA, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC / CE

Psychiatry Mid-Year Review: Data Highlights on Antipsychotic Therapies

Authors: Hannah Brown, MD; Alan Breier, MD; Christoph U. Correll, MD
CME / ABIM MOC / CE Released: 8/9/2023
Valid for credit through: 8/9/2024, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 0.50 ABIM MOC points

Nurses - 0.50 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for psychiatrists, primary care physicians, nurse practitioners (NPs), physician's assistants (PAs), nurses, and other clinicians involved in the care of patients with schizophrenia.

The goal of this activity is for learners to be better able to evaluate key data related to antipsychotic treatments presented at key psychiatric conferences in 2023.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Recent data pertaining to the recognition of schizophrenia
- Recent data pertaining to antipsychotic therapies studied for the management of schizophrenia
Have greater confidence in
- Their ability to evaluate recent clinical data for clinical practice

Disclosures

Disclosures for additional planners can be found here.

Moderator

Hannah Brown, MD

Assistant Professor
Department of Psychiatry
Boston University
Chobanian and Avedisian School of Medicine
Boston, Massachusetts, United States

Disclosures

Hannah Brown, MD, has no relevant financial relationships.

Faculty

Alan Breier, MD

Professor of Psychiatry
Indiana University School of Medicine
Indianapolis, Indiana, United States

Disclosures

Alan Breier, MD, has the following relevant financial relationships:
Consultant or advisor for: Arrivo Bioventures; BioXcel Therapeutics; Karuna Therapeutics; Neumarker Inc.; Perception Neuroscience; Sirtsei Pharmaceuticals, Inc.
Stock options from: Karuna Therapeutics; Perception Neuroscience
Owns stock (publicly traded) in: Karuna Therapeutics

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra
Northwell, New York
Professor of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany

Disclosures

Christoph U. Correll, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Allergan, Inc.; Angelini Pharma; Aristo Pharma (former); Boehringer Ingelheim Pharmaceuticals, Inc.; Cardio Diagnostics; Cerevel Therapeutics; CNX Therapeutics (former); COMPASS Pathways; Darnitsa (former); Gedeon Richter; Hikma Pharmaceuticals (former); Holmusk; Intra-Cellular Therapies, Inc.; Janssen/Johnson and Johnson; Karuna Therapeutics; LB Pharma; Lundbeck, Inc.; MedAvante-ProPhase; MedinCell; Merck; Mindpax; Mitsubishi Tanabe Pharma Corporation (former); Mylan Laboratories Inc.; Neurocrine Biosciences, Inc.; Newron Pharmaceuticals S.p.A. (former); Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Pharmabrain; PPD Biotech; Recordati; Relmada Therapeutics, Inc.; Reviva Pharmaceuticals Inc.; ROVI; Seqirus; SERVIER; SK Life Science; Sunovion Pharmaceuticals Inc.; Sun Pharmaceutical Industries, Ltd. (former); Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company; Teva Pharmaceuticals; Viatris
Speaker or member of speakers bureau for: AbbVie Inc.; Angelini; Aristo Pharma; Darnitsa; Gedeon Richter; Hikma Pharmaceuticals; Intra-Cellular Therapies, Inc.; Janssen/Johnson and Johnson; Lundbeck, Inc.; Mitsubishi Tanabe Pharma Corporation; Mylan Laboratories Inc.; Otsuka Pharmaceutical Co., Ltd.; Recordati; Seqirus; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceutical Company; Viatris
Research funding from: Janssen; Takeda Pharmaceutical Company
Stock options from: Cardio Diagnostics; LB Pharma; Mindpax; Quantic

Editor

Frances McFarland, PhD, MA

Medical Education Director, Medscape, LLC

Disclosures

Frances McFarland, PhD, MA, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Psychiatry & Mental Health

CME / ABIM MOC / CE

Psychiatry Mid-Year Review: Data Highlights on Antipsychotic Therapies

Authors: Hannah Brown, MD; Alan Breier, MD; Christoph U. Correll, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 8/9/2023

Valid for credit through: 8/9/2024, 11:59 PM EST

processing....

Educational Impact Challenge

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

Page 1 of 4

CME / ABIM MOC / CE Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Moderator

Hannah Brown, MD

Faculty

Alan Breier, MD

Christoph U. Correll, MD

Editor

Frances McFarland, PhD, MA

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Psychiatry Mid-Year Review: Data Highlights on Antipsychotic Therapies

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Moderator

Hannah Brown, MD

Faculty

Alan Breier, MD

Christoph U. Correll, MD

Editor

Frances McFarland, PhD, MA

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Psychiatry Mid-Year Review: Data Highlights on Antipsychotic Therapies

Educational Impact Challenge